IBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio Shareholders of a Lead Plaintiff Deadline of August 29, 2023

NEW YORK, Aug. 4, 2023

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/immunitybio-class-action-loss-submission-form/?id=42953&from=4

The lawsuit seeks to recover losses for shareholders who purchased ImmunityBio between May 23, 2022 and May 10, 2023.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until August 29, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, ImmunityBio, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, Good Manufacturing Practice ("GMP") deficiencies at its third-party contract manufacturing organizations ("CMOs") for the antibody cytokine fusion protein N-803, commercially referred to as "Anktiva"; (ii) one or more of the Company's third-party CMOs for Anktiva did in fact suffer from GMP deficiencies; (iii) the foregoing deficiencies was likely to cause the FDA to reject the Anktiva Biologics License Application ("BLA") in its present form; (iv) accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887